Amneal Pharmaceuticals (AMRX) Non-Current Deferred Tax Liability (2017 - 2018)

Amneal Pharmaceuticals has reported Non-Current Deferred Tax Liability over the past 2 years, most recently at $1.2 million for Q4 2018.

For Q4 2018, Non-Current Deferred Tax Liability fell 64.16% year-over-year to $1.2 million; the TTM value through Dec 2018 reached $1.2 million, down 64.16%, while the annual FY2018 figure was $1.2 million, 64.16% down from the prior year.
Non-Current Deferred Tax Liability for Q4 2018 was $1.2 million at Amneal Pharmaceuticals, down from $1.8 million in the prior quarter.
Over five years, Non-Current Deferred Tax Liability peaked at $3.3 million in Q4 2017 and troughed at $1.2 million in Q4 2018.

Peer Comparison